Modality
Small Molecule
MOA
BETi
Target
C5
Pathway
Cell Cycle
ADPKD
Development Pipeline
Preclinical
~Jan 2020
→ ~Apr 2021
Phase 1
Jul 2021
Phase 1Current
NCT08650235
512 pts·ADPKD
2021-07→TBD·Recruiting
512 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
Q3
P1
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08650235 | Phase 1 | ADPKD | Recruiting | 512 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| BII-1564 | Biogen | Phase 2 | PSMA | |
| Sovanaritide | Argenx | Phase 3 | TNFα |